NASDAQ:SHPG - Shire Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $172.54 +0.48 (+0.28 %) (As of 07/18/2018 02:59 AM ET)Previous Close$172.06Today's Range$171.64 - $172.9952-Week Range$123.73 - $177.51Volume375,100 shsAverage Volume1.36 million shsMarket Capitalization$52.55 billionP/E Ratio11.39Dividend Yield0.61%Beta1.28 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland. Receive SHPG News and Ratings via Email Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:SHPG CUSIPN/A Webwww.shire.com Phone353-1609-6000 Debt Debt-to-Equity Ratio0.45 Current Ratio1.14 Quick Ratio0.66 Price-To-Earnings Trailing P/E Ratio11.39 Forward P/E Ratio11.30 P/E Growth1.43 Sales & Book Value Annual Sales$15.16 billion Price / Sales3.46 Cash Flow$22.6728 per share Price / Cash7.61 Book Value$119.43 per share Price / Book1.44 Profitability EPS (Most Recent Fiscal Year)$15.15 Net Income$4.27 billion Net Margins28.96% Return on Equity13.60% Return on Assets6.92% Miscellaneous Employees23,044 Outstanding Shares303,950,000Market Cap$52,547.74 Shire (NASDAQ:SHPG) Frequently Asked Questions What is Shire's stock symbol? Shire trades on the NASDAQ under the ticker symbol "SHPG." How often does Shire pay dividends? What is the dividend yield for Shire? Shire announced a semiannual dividend on Friday, February 16th. Shareholders of record on Friday, March 9th will be paid a dividend of $0.8937 per share on Tuesday, April 24th. This represents a yield of 1.33%. The ex-dividend date of this dividend is Thursday, March 8th. This is a boost from Shire's previous semiannual dividend of $0.15. View Shire's Dividend History. How were Shire's earnings last quarter? Shire PLC (NASDAQ:SHPG) released its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $3.58 by $0.28. The biopharmaceutical company had revenue of $3.77 billion for the quarter. Shire had a net margin of 28.96% and a return on equity of 13.60%. The firm's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the firm earned $3.63 earnings per share. View Shire's Earnings History. When is Shire's next earnings date? Shire is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Shire. What guidance has Shire issued on next quarter's earnings? Shire issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.23. The company issued revenue guidance of $15.4-15.9 billion, compared to the consensus revenue estimate of $15.48 billion. What price target have analysts set for SHPG? 17 brokers have issued 1-year price targets for Shire's stock. Their forecasts range from $150.00 to $245.00. On average, they expect Shire's share price to reach $201.00 in the next twelve months. This suggests a possible upside of 16.5% from the stock's current price. View Analyst Ratings for Shire. What is the consensus analysts' recommendation for Shire? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shire in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Shire stock? Here are some recent quotes from research analysts about Shire stock: 1. According to Zacks Investment Research, "Sales of Shire’s Mydayis showed promise in the first six months of launch. Also, strong performance of Vyvanse, Cinryze and Elaprase continue to drive its top line. The label expansion of Firazyr in pediatrics and approval of Lyophilized Oncaspar in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. Though the adult ADHD space is one of the largest and fastest growing segments of the market, it is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past year. Estimates movement remains mixed ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/23/2018) 2. Cantor Fitzgerald analysts commented, "Though it has not been confirmed by Shire yet, headlines from Reuters are reporting that Takeda (Not Covered) has made a takeover offer to Shire worth ~46.50 pounds/share (~$198 per ADS), which we estimate translates to ~ $61B (see Exhibit 1 on page 3 for details). Based on our conversations with shareholders, this seems like a reasonable starting price for a negotiation, but we think people will want to see $200+ unless it’s all cash." (4/16/2018) 3. Royal Bank of Canada analysts commented, "We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth." (2/5/2018) Are investors shorting Shire? Shire saw a drop in short interest in June. As of June 15th, there was short interest totalling 1,426,267 shares, a drop of 23.1% from the May 31st total of 1,853,536 shares. Based on an average trading volume of 829,895 shares, the short-interest ratio is currently 1.7 days. Approximately 0.5% of the shares of the company are short sold. View Shire's Current Options Chain. Who are some of Shire's key competitors? Some companies that are related to Shire include Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Vertex Pharmaceuticals (VRTX) and Zoetis (ZTS). Who are Shire's key executives? Shire's management team includes the folowing people: Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)Gisele Dion, Chief Accounting OfficerMr. Matthew Walker, Head of Technical Operations (Age 54)Prof. Andreas Busch Ph.D., Head of R&D & Chief Scientific Officer (Age 55) Has Shire been receiving favorable news coverage? News articles about SHPG stock have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Shire earned a daily sentiment score of 0.07 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 45.68 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. Who are Shire's major shareholders? Shire's stock is owned by a number of of institutional and retail investors. Top institutional investors include Gateway Investment Advisers LLC (0.02%), Columbia Partners L L C Investment Management (0.01%), Havens Advisors LLC (0.01%), Bank of Montreal Can (0.01%), Addenda Capital Inc. (0.00%) and Fisher Asset Management LLC (0.00%). View Institutional Ownership Trends for Shire. Which major investors are selling Shire stock? SHPG stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. View Insider Buying and Selling for Shire. Which major investors are buying Shire stock? SHPG stock was acquired by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Havens Advisors LLC, Bank of Montreal Can, Addenda Capital Inc., Bremer Trust National Association, Columbia Partners L L C Investment Management, Hills Bank & Trust Co. and Addenda Capital Inc.. View Insider Buying and Selling for Shire. How do I buy shares of Shire? Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Shire's stock price today? One share of SHPG stock can currently be purchased for approximately $172.54. How big of a company is Shire? Shire has a market capitalization of $52.55 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. Shire employs 23,044 workers across the globe. How can I contact Shire? Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected] MarketBeat Community Rating for Shire (NASDAQ SHPG)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 964 (Vote Outperform)Underperform Votes: 495 (Vote Underperform)Total Votes: 1,459MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?